One must bear in mind that whilst some of the MTA target molecular alterations that have not been proven to be drivers for any specific disease (e.g. PI3KCA mutations), other MTA target clear defined oncogenic aberrations (e.g. EGFR mutations in non-small cell lung cancer –NSCLC-). This evidence concerns the gene EGFR and non-small cell lung carcinoma.